Biomarkers /
MET
Overview
MET (MET proto-oncogene, receptor tyrosine kinase) encodes the hepatocyte growth factor receptor protein. Germline mutations in the tyrosine kinase domain of MET occur in 100% of hereditary papillary renal cell carcinoma (PMID: 9140397). Somatic MET mutations and/or amplifications have been observed in sporadic papillary renal cell carcinoma, head and neck squamous cell carcinoma (PMID: 10734314), childhood hepatocellular carcinoma (PMID: 9927037), lung cancer (PMID: 14559814; PMID: 17463250), gastric cancer (PMID: 10223227), esophageal cancer (PMID: 16186806), colorectal cancer (PMID: 10343196), gliomas (PMID: 18077431), and clear cell ovarian cancer (PMID: 21478826). In the context of malignancy, aberrant signaling through the MET receptor promotes pleiotrophic effects including growth, survival, invasion, migration, angiogenesis and metastasis (Birchmeier et al. 2003; Peruzzi and Bottaro 2006).
MET is altered in 2.60% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MET are MET Mutation (1.90%), MET Amplification (0.69%), MET Exon 14 Mutation (0.23%), MET c.1078-c.1345 Missense (0.15%), and MET X1010_splice (0.13%) [3].
Biomarker-Directed Therapies
MET is a predictive biomarker for use of capmatinib, crizotinib, afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cemiplimab, pembrolizumab, and tepotinib in patients.
Non-small cell lung carcinoma has the most therapies with MET as a predictive biomarker.
Of the therapies with MET as a predictive biomarker, 4 are FDA-approved in at least one clinical setting and 9 have NCCN guidelines in at least one clinical setting.
MET Amplification, MET Exon 14 Skipping, MET Overexpression, TPR-MET Fusion, and MET Expression are the top alterations on MET targeted by therapies [4].
Afatinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Capmatinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (FDA, NCCN) | |
Note: Indicated for adult patients with metastatic non-small cell lung cancer with a mutation that leads to MET exon 14 skipping. |
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) | |
Note: Recommended by NCCN for patients with high-level MET amplification. |
Crizotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) | |
Note: Recommended by NCCN under Category 2A for patients with high-level MET amplification or MET exon 14 skipping mutations. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Osimertinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: MET amplification renders the EGFR kinase resistant to EGFR TKIs, leading to primary or acquired resistance. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (FDA, NCCN) | |
Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with a ROS1, RET, BRAF V600E, or MET Exon 14 Skipping alteration: approved as a single agent for first- or subsequent-line therapy. However, per NCCN, targeted therapy for the oncogenic driver should take precedence over an immune checkpoint inhibitor. |
Tepotinib +
Non-Small Cell Lung Carcinoma -
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
MET status serves as an inclusion eligibility criteria in 90 clinical trials, of which 53 are open and 37 are closed. Of the trials that contain MET status as an inclusion criterion, 3 are early phase 1 (1 open), 28 are phase 1 (12 open), 10 are phase 1/phase 2 (5 open), 44 are phase 2 (32 open), 4 are phase 3 (2 open), and 1 is no phase specified (1 open).
Trials with MET status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, malignant solid tumor, breast carcinoma, non-squamous non-small cell lung carcinoma, and adenocarcinoma of the gastroesophageal junction [4].
The most frequent alterations to serve as inclusion eligibility criteria are MET Amplification, MET Overexpression, MET Exon 14 Skipping, MET Mutation, and MET Fusion [4].
Crizotinib, capmatinib, savolitinib, cabozantinib, and placebo are the most frequent therapies in trials with MET as an inclusion criteria [4].
Significance of MET in Diseases
Non-Small Cell Lung Carcinoma +
MET is altered in 5.01% of non-small cell lung carcinoma patients [3].
MET is an inclusion criterion in 41 clinical trials for non-small cell lung carcinoma, of which 28 are open and 13 are closed. Of the trials that contain MET status and non-small cell lung carcinoma as inclusion criteria, 11 are phase 1 (6 open), 5 are phase 1/phase 2 (4 open), 23 are phase 2 (17 open), and 2 are phase 3 (1 open) [4].
Capmatinib, afatinib, crizotinib, dacomitinib, erlotinib, gefitinib, osimertinib, pembrolizumab, and tepotinib have evidence of efficacy in patients with MET mutation in non-small cell lung carcinoma [4].
Malignant Solid Tumor +
MET is altered in 2.83% of malignant solid tumor patients [3].
MET is an inclusion criterion in 27 clinical trials for malignant solid tumor, of which 14 are open and 13 are closed. Of the trials that contain MET status and malignant solid tumor as inclusion criteria, 13 are phase 1 (4 open), 6 are phase 1/phase 2 (3 open), and 8 are phase 2 (7 open) [4].
Breast Carcinoma +
MET is altered in 1.14% of breast carcinoma patients [3].
MET is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 4 are open and 4 are closed. Of the trials that contain MET status and breast carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
MET is altered in 4.29% of adenocarcinoma of the gastroesophageal junction patients [3].
MET is an inclusion criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 3 are closed. Of the trials that contain MET status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (2 open) [4].
Colorectal Carcinoma +
MET is altered in 2.14% of colorectal carcinoma patients [3].
MET is an inclusion criterion in 7 clinical trials for colorectal carcinoma, of which 3 are open and 4 are closed. Of the trials that contain MET status and colorectal carcinoma as inclusion criteria, 5 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Hepatocellular Carcinoma +
MET is altered in 2.59% of hepatocellular carcinoma patients [3].
MET is an inclusion criterion in 7 clinical trials for hepatocellular carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MET status and hepatocellular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].
Melanoma +
MET is altered in 6.7% of melanoma patients [3].
MET is an inclusion criterion in 6 clinical trials for melanoma, of which 3 are open and 3 are closed. Of the trials that contain MET status and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 3 are phase 2 (2 open) [4].
Gastric Adenocarcinoma +
MET is altered in 3.56% of gastric adenocarcinoma patients [3].
MET is an inclusion criterion in 6 clinical trials for gastric adenocarcinoma, of which 3 are open and 3 are closed. Of the trials that contain MET status and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 4 are phase 2 (2 open) [4].
Gastric Carcinoma +
MET is altered in 3.53% of gastric carcinoma patients [3].
MET is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MET status and gastric carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (0 open) [4].
Squamous Cell Lung Carcinoma +
MET is altered in 3.25% of squamous cell lung carcinoma patients [3].
MET is an inclusion criterion in 4 clinical trials for squamous cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain MET status and squamous cell lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) and 1 is no phase specified (1 open) [4].
Head And Neck Squamous Cell Carcinoma +
MET is altered in 2.75% of head and neck squamous cell carcinoma patients [3].
MET is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Bladder Carcinoma +
MET is altered in 2.77% of bladder carcinoma patients [3].
MET is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Head And Neck Carcinoma +
MET is altered in 2.08% of head and neck carcinoma patients [3].
MET is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Prostate Carcinoma +
MET is altered in 1.29% of prostate carcinoma patients [3].
MET is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MET status and prostate carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Endometrial Carcinoma +
MET is altered in 4.83% of endometrial carcinoma patients [3].
MET is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Renal Cell Carcinoma +
MET is altered in 3.94% of renal cell carcinoma patients [3].
MET is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MET status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Urothelial Carcinoma +
MET is altered in 2.83% of urothelial carcinoma patients [3].
MET is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Colorectal Adenocarcinoma +
MET is altered in 2.14% of colorectal adenocarcinoma patients [3].
MET is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].
Ovarian Carcinoma +
MET is altered in 1.59% of ovarian carcinoma patients [3].
MET is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Pancreatic Adenocarcinoma +
MET is altered in 0.9% of pancreatic adenocarcinoma patients [3].
MET is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Pancreatic Carcinoma +
MET is altered in 0.89% of pancreatic carcinoma patients [3].
MET is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MET status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Papillary Renal Cell Carcinoma +
MET is altered in 16.9% of papillary renal cell carcinoma patients [3].
MET is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].
Malignant Uterine Neoplasm +
MET is altered in 3.8% of malignant uterine neoplasm patients [3].
MET is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MET status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
MET is altered in 5.21% of non-squamous non-small cell lung carcinoma patients [3].
MET is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Cervical Squamous Cell Carcinoma +
MET is altered in 2.26% of cervical squamous cell carcinoma patients [3].
MET is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Small Intestinal Adenocarcinoma +
MET is altered in 1.87% of small intestinal adenocarcinoma patients [3].
MET is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MET status and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Esophageal Squamous Cell Carcinoma +
MET is altered in 2.1% of esophageal squamous cell carcinoma patients [3].
MET is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
MET is altered in 1.61% of high grade ovarian serous adenocarcinoma patients [3].
MET is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
MET is altered in 0.95% of B-cell non-hodgkin lymphoma patients [3].
MET is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Medullary Carcinoma +
MET is altered in 0.63% of thyroid gland medullary carcinoma patients [3].
MET is an inclusion criterion in 1 clinical trial for thyroid gland medullary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Alveolar Soft Part Sarcoma +
MET is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Bronchogenic Carcinoma +
MET is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Clear Cell Sarcoma Of Soft Tissue +
MET is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MET status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [4].
Diffuse Intrinsic Pontine Glioma +
MET is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains MET status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Hepatoblastoma +
MET is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Wilms Tumor +
MET is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MET status and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.